<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02488928</url>
  </required_header>
  <id_info>
    <org_study_id>2015-1676</org_study_id>
    <nct_id>NCT02488928</nct_id>
  </id_info>
  <brief_title>E- Predict: EBUS ELASTOGRAPHY STRAIN in Lung Cancer</brief_title>
  <acronym>E-PREDICT</acronym>
  <official_title>E-PREDICT Evaluating the Predictive Value of EBUS ELASTOGRAPHY STRAIN in Patients With (Suspected) Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EBUS elastography is a method to determine stiffness of lymph nodes, based on the minute&#xD;
      deformation of the node by the beating heart. Whether EBUS elastography may further increase&#xD;
      the sensitivity to predict the presence or absence of malignancy is unclear.&#xD;
&#xD;
      We suggest to use EBUS elastography strain pattern analysis for this assessment and correlate&#xD;
      these measurements with the final pathology outcome to determine NPV, PPV, sensitivity and&#xD;
      specificity of this analysis to predict the presence or absence of malignancy in patients&#xD;
      with (suspected) lung cancer in a prospectively obtained observational cohort study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will undergo a routine EBUS and/or EUS or EUSb with Pentax series EBUS or EUS scopes&#xD;
      in combination with Hitachi Preirus Hi-Vision ultrasound processor with installed&#xD;
      elastography software. Normal international guidelines for staging, diagnosis and specimen&#xD;
      acquisition will be followed. For a normal evaluation B-mode measurements from all lymph node&#xD;
      regions are obtained assessing size and standard ultrasound characteristics and all lymph&#xD;
      nodes in the regions of interest that meet the criteria for fine needle aspiration will be&#xD;
      sampled. For this study, in addition to the normal B-mode assessment of five sonographic&#xD;
      B-mode characteristics elastography strain graph video, elastography image, and a strain&#xD;
      histogram from the region of interest will be obtained.&#xD;
&#xD;
      Fine needle aspiration for cytology evaluation will be obtained from nodes based on imaging&#xD;
      characteristics or standard sonography characteristics following current everyday clinical&#xD;
      practice and the international guidelines. Subsequently, the patient charts will be&#xD;
      retrospectively analysed after completion of the diagnostic and/or surgical treatment of the&#xD;
      (suspected) lung cancer to match the obtained imaging data to pathology results (cytology and&#xD;
      or histology where present) and clinical follow up until 6 months after the diagnostic&#xD;
      procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">April 2019</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>stiffness of lymph nodes</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 4 hours</time_frame>
    <description>stiffness/strain is a relative measure and has therefor no units</description>
  </primary_outcome>
  <enrollment type="Actual">327</enrollment>
  <condition>Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with suspected or proven lung cancer are eligible if there is an indication for&#xD;
        EBUS, EUS or combined EBUS and EUSb (single scope, EUS with EBUS scope). Eligible are&#xD;
        patients with no contra-indications for EBUS.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with indication for diagnostic or staging EBUS procedure for suspected or&#xD;
             proven lung cancer.&#xD;
&#xD;
          -  ASA physical status 1-3.&#xD;
&#xD;
          -  Age 18 years or older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bleeding disorders.&#xD;
&#xD;
          -  Contra-indication for temporary interruption of the use of anticoagulant therapy&#xD;
             (acenocoumarol, warfarin, therapeutic dose of low molecular weight heparines or&#xD;
             clopidrogel).&#xD;
&#xD;
          -  Known allergy for lidocaine.&#xD;
&#xD;
          -  Uncontrolled pulmonary hypertension.&#xD;
&#xD;
          -  Recent and/or uncontrolled cardiac disease.&#xD;
&#xD;
          -  Compromised upper airway (eg concomitant head and neck cancer or central airway&#xD;
             stenosis for any reason).&#xD;
&#xD;
          -  Prior radiotherapy treatment involving the central airways&#xD;
&#xD;
          -  ASA classification greater than or equal to 4.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Inability to consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik van der Heijden, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>chest physician</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>Dk 2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interventional Pulmonology Unit Policlinico S. Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria di Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ausl Modena - Ospedale Santa Maria Bianca</name>
      <address>
        <city>Modena</city>
        <zip>41037</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pesaro-Fano Hospital</name>
      <address>
        <city>Pesaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RadboudUMC</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>June 19, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2015</study_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>EBUS</keyword>
  <keyword>elastography</keyword>
  <keyword>predictive value</keyword>
  <keyword>strain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

